EDITORIALS

Late Toxicities of Drugs: Bisphosphonates

Bruce A. Chabner
The Oncologist 2005; 10: 301-303; doi:10.1634/theoncologist.10-5-301
[Full Text] [PDF] [Supplemental Data]  

Regarding "Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases"

Karen Parles
The Oncologist 2005; 10: 304-305; doi:10.1634/theoncologist.10-5-304
[Full Text] [PDF]  

The Issue of Renal Safety of Zoledronic Acid from a Nephrologist’s Point of View

József Balla
The Oncologist 2005; 10: 306-308; doi:10.1634/theoncologist.10-5-306
[Full Text] [PDF]  

"Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid": Not So Safe

Gilles Lugassy
The Oncologist 2005; 10: 309-310; doi:10.1634/theoncologist.10-5-309
[Full Text] [PDF]  

Response to Letters to the Editor from Lugassy and Balla Regarding "Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid"

James Berenson
The Oncologist 2005; 10: 311-312; doi:10.1634/theoncologist.10-5-311
[Full Text] [PDF]  

Safety and Compliance of Intravenous and Oral Dosing Regimens

Graham Jackson
The Oncologist 2005; 10: 313-314; doi:10.1634/theoncologist.10-5-313
[Full Text] [PDF]  

In Response to Jackson Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens"

PierFranco Conte, Valentina Guarneri
The Oncologist 2005; 10: 315-316; doi:10.1634/theoncologist.10-5-315
[Full Text] [PDF]  

Bisphosphonate Safety and Tolerability

Jean-Jacques Body
The Oncologist 2005; 10: 317; doi:10.1634/theoncologist.10-5-317
[Full Text] [PDF]  

In Response to Body Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens"

PierFranco Conte, Valentina Guarneri
The Oncologist 2005; 10: 318-319; doi:10.1634/theoncologist.10-5-318
[Full Text] [PDF]  

New Combinations in Metastatic Colorectal Cancer: What Are Our Expectations?

Herbert Hurwitz
The Oncologist 2005; 10: 320-322; doi:10.1634/theoncologist.10-5-320
[Full Text] [PDF]  

Section Editor’s Note

Franco Muggia
The Oncologist 2005; 10: 323-324; doi:10.1634/theoncologist.10-5-323
[Full Text] [PDF]  

Adjuvant Therapy in Stage II Colon Cancer: Current Approaches

Lisa Baddi, Al Benson, III
The Oncologist 2005; 10: 325-331; doi:10.1634/theoncologist.10-5-325
[Full Text] [PDF]  

Stage II Colorectal Cancer: To Treat or not to Treat

Patrick G. Johnston
The Oncologist 2005; 10: 332-334; doi:10.1634/theoncologist.10-5-332
[Full Text] [PDF]  

Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection?

Vivek Patel, Joseph B. Shrager
The Oncologist 2005; 10: 335-344; doi:10.1634/theoncologist.10-5-335
[Abstract] [Full Text] [PDF]  

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum

Román Pérez-Soler, Jean Pierre Delord, Allan Halpern, Karen Kelly, James Krueger, Bartomeu Massutí Sureda, Joachim von Pawel, Jennifer Temel, Salvatore Siena, Denis Soulières, Leonard Saltz, James Leyden
The Oncologist 2005; 10: 345-356; doi:10.1634/theoncologist.10-5-345
[Abstract] [Full Text] [PDF]  

Effect of Patient Exclusion Criteria on the Efficacy of Erythropoiesis-Stimulating Agents in Patients with Cancer-Related Anemia

Timothy J. Littlewood, Brad Schenkel, Martin Liss
The Oncologist 2005; 10: 357-360; doi:10.1634/theoncologist.10-5-357
[Abstract] [Full Text] [PDF]  

The Molecular Perspective: Double-Stranded DNA Breaks

David S. Goodsell
The Oncologist 2005; 10: 361-362; doi:10.1634/theoncologist.10-5-361
[Full Text] [PDF]  

Reflections

The Oncologist 2005; 10: 361-363; doi:10.1634/theoncologist.10-5-361
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.